Company Overview
| Stock Name | Ascletis-B |
|---|---|
| Stock Code | 01672 |
| Company Full Name | To be extracted |
| Industry | 醫療保健 |
| Principal Activities | 公司主要於中國從事生物制品研發。 |
| Listing Date | 2018-08-01 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國浙江省杭州市濱江區江漢路1785號雙城國際4幢18層 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.ascletis.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 14.00 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 18.8% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 313,796,000 |
Stock Connect Inclusion
| HK Market Cap | --- |
|---|
| 26Q2 Regular Review | |
| Inclusion Pathway | None |
|---|---|
| Est. Threshold | --- |
| Analysis Result | 无法确定入通路径 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 14.0 |
|---|---|
| First Day Open | HK$ 14.8 |
| First Day Change | 19.57% |
| First Day Volume | 82741300.0 |
| First Day Turnover | 1179890000.0 |
Use of Proceeds
| Use of Proceeds | 1、約30.0%或892.8百萬港元將用于我們核心產品線的持續研發； 2、約25.0%或744.0百萬港元將用于戈諾衛及拉維達韋商業化； 3、約15.0%或446.4百萬港元將用于尋求新在研藥物的引進許可，盡管我們截至最后實際可行日期尚未物色到任何潛在目標； 4、約10.0%或297.6百萬港元將用于通過啟動及進行臨床試驗進行ASC21的研發； 5、約10.0%或297.6百萬港元將用于支持我們的研發基礎設施及HBV及NASH發現階段兩個內部藥物計劃的早期開發； 6、約10%或297.6百萬港元將用于我們的營運資金及作其他一般公司用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (3)
Overall Coordinators (3)
Joint Bookrunners (3)
Joint Lead Managers (3)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | GIC Private Limited | 588,588,000 HKD | — | 18.76% | — | 6 months | 2019-02-01 |
Directors & Management
| Chairman | 吳勁梓 |
|---|---|
| Company Secretary | 鐘明輝 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 吳勁梓(55.15%);傅唯(5.90%);JJW11 Limited(5.85%) |
|---|
